First-of-its-kind hydrogel platform enables on-demand production of medicines, chemicals

Led by Hal Alper, professor at The University of Texas at Austin's Cockrell School of Engineering, in collaboration with chemist Alshakim Nelson and his research group at the University of Washington, this first-of-its-kind system effectively embeds microbial biofactories -- cells bioengineered to overproduce a product -- into the solid support of a hydrogel, allowing for portability and optimized production. It is the first hydrogel-based system to organize both individual microbes and consortia for in-the-moment production of high-value chemical feedstocks, used for processes such as fuel production, and pharmaceuticals. Products can be produced within a couple of hours to a couple of days.

The team describes their new approach in the Feb. 4 issue of Nature Communications.

"We have taken a completely different angle for fermentation by utilizing hydrogels," said Alper, whose research expertise is focused in biotechnology and cellular engineering. "Many of the chemicals, fuels, nutraceuticals and pharmaceuticals we use rely on traditional fermentation technology. Our technology addresses a strong limitation in the fields of synthetic biology and bioprocessing, namely the ability to provide a means for both on-demand and repeated-use production of chemicals and antibiotics from both mono- and co-cultures."

As a crosslinked polymer, the hydrogel used in this work can be 3D printed or manually extruded. The gel material, along with the cells inside, can flow like a liquid and then harden upon exposure to UV light. Molecularly, the resulting polymer network is large enough for molecules and proteins to move through it, but the space is too small for cells to leak out.

The team also found that by lyophilizing, or freeze-drying, the hydrogel system, it can effectively preserve the fermentation capacity of the biofactories until needed in the future. The result of the freeze-drying somewhat resembles an ancient mummy, shriveled up but well-preserved. To revive the hydrogel and enable the production of the chemical or pharmaceutical, one would simply add water, sugar and/or some other basic nutrients, and the cells will then convert into the product just as effectively as before the preservation process.

One of the novel aspects enabled by this platform is the ability to combine multiple different organisms, called consortia, together in a way that outperforms traditional, large-scale bioreactors. In particular, this system enables a plug-and-play approach to combining and optimizing chemical production. For example, if one set of enzymes works best in the bacteria E. coli, while the other works best in the yeast S. cerevisiae, the two organisms can work together to more efficiently go straight to the product. The research team tested both of these organisms.

This platform has the added benefit of multitasking, keeping different types of cells separated while they grow, preventing one from taking over and killing off the others. Likewise, by testing a range of temperatures, the team was able to control the dynamics of the system, keeping the growth of multiple cell types balanced.

Finally, the team was able to show continuous, repeated use of the system (with yeast cells) over the course of an entire year without a decrease in yields, indicating the sustainability of the process over time.

Medicines such as antibiotics have a certain shelf life and require particular storage conditions. The portability of the biofactory to make these molecules makes the hydrogel system especially useful in remote places, without access to refrigeration to store medications. It would also be a small and compact way to maintain access to several medications and other essential chemicals when there is no access to a pharmacy or a store, like during a military mission or a mission to Mars. Although not quite there yet, the possibilities are promising.

"This technology can be applied to a wide range of products and cell types. We see engineers and scientists being able to plug and play with different consortia of cells to produce diverse products that are needed for a specific scenario," Alper said. "That's part of what makes this technology so exciting."